Related references
Note: Only part of the references are listed.High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
J. -Y. Pierga et al.
ANNALS OF ONCOLOGY (2012)
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Linda Sofie Lindstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
Jean-Yves Pierga et al.
LANCET ONCOLOGY (2012)
Biomarkers characterization of circulating tumour cells in breast cancer patients
Rosa Nadal et al.
BREAST CANCER RESEARCH (2012)
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi et al.
CLINICAL CANCER RESEARCH (2011)
Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival
Sjoerd T. Ligthart et al.
PLOS ONE (2011)
FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform
Julie Ann Mayer et al.
CANCER GENETICS (2011)
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2010)
All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer
F. A. W. Coumans et al.
ANNALS OF ONCOLOGY (2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
Seigo Nakamura et al.
BREAST CANCER (2010)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C. Simmons et al.
ANNALS OF ONCOLOGY (2009)
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Minetta C. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Variation of circulating tumor cell levels during treatment of metastatic breast cancer:: prognostic and therapeutic implications
F. Nole et al.
ANNALS OF ONCOLOGY (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues
Songdong Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
